Wells Fargo’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.62M Sell
123,037
-20,728
-14% -$1.07M ﹤0.01% 2327
2026
Q1
$7.3M Buy
143,765
+18,958
+15% +$884K ﹤0.01% 2276
2025
Q4
$3.68M Buy
124,807
+12,455
+11% +$338K ﹤0.01% 2956
2025
Q3
$2.9M Buy
112,352
+16,969
+18% +$473K ﹤0.01% 3041
2025
Q2
$2.63M Buy
95,383
+10,523
+12% +$277K ﹤0.01% 2996
2025
Q1
$2.41M Sell
84,860
-420,867
-83% -$14.9M ﹤0.01% 3026
2024
Q4
$21M Buy
505,727
+185,206
+58% +$8.85M ﹤0.01% 1317
2024
Q3
$21.4M Sell
320,521
-95,959
-23% -$8.81M ﹤0.01% 1258
2024
Q2
$49.5M Buy
416,480
+142,980
+52% +$18.1M 0.01% 778
2024
Q1
$29.1M Buy
273,500
+12,822
+5% +$1.29M 0.01% 1008
2023
Q4
$25.9M Sell
260,678
-42,533
-14% -$3.58M 0.01% 1020
2023
Q3
$31.3M Sell
303,211
-14,210
-4% -$1.59M 0.01% 879
2023
Q2
$38.6M Sell
317,421
-20,138
-6% -$2.69M 0.01% 804
2023
Q1
$51.8M Buy
337,559
+19,953
+6% +$3.29M 0.01% 680
2022
Q4
$57M Sell
317,606
-35,437
-10% -$5.79M 0.02% 627
2022
Q3
$41.7M Sell
353,043
-9,780
-3% -$1.48M 0.01% 723
2022
Q2
$51.8M Sell
362,823
-66,786
-16% -$9.55M 0.02% 658
2022
Q1
$74M Sell
429,609
-39,521
-8% -$6.65M 0.02% 602
2021
Q4
$119M Sell
469,130
-101,312
-18% -$29.6M 0.03% 429
2021
Q3
$220M Buy
570,442
+195,101
+52% +$72M 0.05% 383
2021
Q2
$88.2M Sell
375,341
-8,383
-2% -$1.5M 0.02% 748
2021
Q1
$50.2M Sell
383,724
-33,989
-8% -$4.93M 0.01% 1046
2020
Q4
$43.6M Buy
417,713
+160,677
+63% +$16.3M 0.01% 1061
2020
Q3
$18.2M Buy
257,036
+2,460
+1% +$172K 0.01% 1477
2020
Q2
$16.3M Buy
254,576
+100,760
+66% +$5.52M ﹤0.01% 1492
2020
Q1
$4.61M Buy
153,816
+54,706
+55% +$1.26M ﹤0.01% 2297
2019
Q4
$1.94M Buy
99,110
+33,257
+51% +$590K ﹤0.01% 3368
2019
Q3
$1.05M Buy
65,853
+52,140
+380% +$770K ﹤0.01% 3802
2019
Q2
$201K Buy
13,713
+709
+5% +$15.2K ﹤0.01% 4971
2019
Q1
$265K Buy
13,004
+8,266
+174% +$153K ﹤0.01% 4678
2018
Q4
$72K Buy
+4,738
New +$77.9K ﹤0.01% 5420

Other funds holding MRNA

Wells Fargo's MRNA Position: Q2 2026 in Review

Wells Fargo reduced its Moderna (MRNA) stake by 14% in Q2 2026, selling an estimated $1.07M and leaving 123,037 shares worth $8.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2327.

Wells Fargo first reported a position in MRNA in Q4 2018 and has held it in 31 quarters since. The position peaked at $220M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Wells Fargo held 123,037 shares of Moderna worth $8.62M as of Q2 2026.
  • Wells Fargo sold 20,728 Moderna shares in Q2 2026, an estimated $1.07M.
  • Moderna made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2327 holding.
  • Wells Fargo first reported a position in Moderna in Q4 2018 and has held it in 31 quarters since.
  • Wells Fargo's Moderna position peaked at $220M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.